<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783181</url>
  </required_header>
  <id_info>
    <org_study_id>CAH-301</org_study_id>
    <nct_id>NCT04783181</nct_id>
  </id_info>
  <brief_title>A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)</brief_title>
  <official_title>A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrenas Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adrenas Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based&#xD;
      BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive a single dose of intravenous (IV) BBP-631 and are monitored for 52&#xD;
      weeks post-treatment. All participants who receive AAV5 based BBP-631 will be followed for an&#xD;
      additional 4 years for safety and efficacy in a separate long-term follow-up study. In total,&#xD;
      all participants will be followed for at least 5 years after the date of treatment with&#xD;
      BBP-631.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Participants will be assigned sequentially to one of 3 dose levels depending on the date of determination of eligibility.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Treatment-emergent Adverse Events that Led to Study Discontinuation</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To select the optimum dose or dose range of BBP 631 for future studies</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 17-OHP (hydroxyprogesterone) levels</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in endogenous cortisol levels</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in androstenedione (A4) levels</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBP-631 lowest dose, administered once, intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBP-631 middle dose, administered once, IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BBP-631, highest dose, administered once, IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV BBP-631</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          1. Adult male and non-pregnant females with classic CAH (simple virilizing or&#xD;
             salt-wasting) due to 21-OHD&#xD;
&#xD;
          2. Screening/baseline 17-OHP levels &gt; 5-10 × ULN and &lt; 40 × ULN (upper limit of normal)&#xD;
&#xD;
          3. Stable oral hydrocortisone (HC) regimen as the only glucocorticoid (GC) maintenance&#xD;
             therapy&#xD;
&#xD;
          4. Naïve to prior gene therapy or AAV-mediated therapy&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          1. Positive for anti-AAV5 (Adeno-Associated Virus Type 5) antibodies&#xD;
&#xD;
          2. History of adrenalectomy and has no significant liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathleen M Kirby</last_name>
    <phone>+1.978.479.7640</phone>
    <email>ClinicalTrials@AdrenasTx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mel Pozun</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norma Martinez</last_name>
      <phone>323-361-5627</phone>
      <email>nzmartinez@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Mimi Kim, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Office of Patient Recruitment</last_name>
      <phone>800-411-1222</phone>
      <email>prpl@cc.nih.gov</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Joyal (Study Coordinator), CRNP</last_name>
      <phone>301-496-8542</phone>
      <email>ejoyal@nih.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Deborah Merke, M.D., M.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator Office</last_name>
      <phone>612-624-8672</phone>
      <email>saraf010@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Coordinator Office</last_name>
      <phone>612-626-7024</phone>
    </contact_backup>
    <investigator>
      <last_name>Kyriakie Sarafoglou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PARC Clinical Research, CALHN Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Heyman</last_name>
      <phone>+61 8 7074 4404</phone>
      <email>Kathy.heyman2@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>David Torpy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://adrenastx.com</url>
    <description>Adrenas Therapeutics Website</description>
  </link>
  <link>
    <url>https://cahgenetherapy.com</url>
    <description>CAH Gene Therapy Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAH</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>AAV</keyword>
  <keyword>AAV5</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

